{
    "2020-01-13": [
        [
            {
                "time": "2020-01-13",
                "original_text": "Brodsky & Smith, LLC Announces an Investigation of Dermira, Inc. - (Nasdaq:DERM)",
                "features": {
                    "keywords": [
                        "Investigation",
                        "Dermira",
                        "Shareholder"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-01-13",
                "original_text": "Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Dermira, Inc. to Eli Lilly and Company is Fair to Shareholders",
                "features": {
                    "keywords": [
                        "Investigation",
                        "Dermira",
                        "Eli Lilly",
                        "Sale"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-01-13",
                "original_text": "Glaxo Files Marketing Application for Fostemsavir in Europe",
                "features": {
                    "keywords": [
                        "Glaxo",
                        "Fostemsavir",
                        "Marketing Application"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-01-13",
                "original_text": "Lilly to Buy Dermira for $1.1B, Add Phase III Eczema Candidate",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Dermira",
                        "Acquisition",
                        "Phase III"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-01-13",
                "original_text": "Should Invesco Defensive Equity ETF (DEF) Be on Your Investing Radar?",
                "features": {
                    "keywords": [
                        "Invesco",
                        "Defensive Equity ETF",
                        "Investing"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-01-13",
                "original_text": "Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?",
                "features": {
                    "keywords": [
                        "Invesco",
                        "Biotechnology",
                        "Genome ETF"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-01-13",
                "original_text": "Tyvyt® (Sintilimab Injection) Combined with ALIMTA® (Pemetrexed) and Platinum Met Predefined Primary Endpoint in Phase 3 ORIENT-11 Study as First-Line Therapy in Nonsquamous NSCLC",
                "features": {
                    "keywords": [
                        "Tyvyt",
                        "Sintilimab",
                        "Phase 3",
                        "Primary Endpoint"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}